Wockhardt Limited
WOCKPHARMA
Classifica tra le azioni
#4514
Wockhardt Limited, together with its subsidiaries, operates as a pharmaceutical... Wockhardt Limited, together with its subsidiaries, operates as a pharmaceutical and biotech company, in India, the United States, the United Kingdom, Switzerland, Ireland, Russia, Europe, and internationally. It manufactures and trades pharmaceuticals, medicinal chemical, and botanical products, as well as chemicals and chemical products. The company also develops its flagship antibiotic, ZAYNICH zidebactam/cefepime, a novel beta lactam enhancer mechanism for the treatment of sepsis and hospital/ventilator associated pneumonia; FOVISCU, an antibiotic for gram-negative infections; MIQNAF nafithromycin, which targets azithromycin-resistant community respiratory pathogens; and ODRATE, a once-daily combination of ertapenem and zidebactam for resistant gram-negative infections through outpatient parenteral antimicrobial therapy. In addition, it develops and commercializes insulin analogs, glucagon-like peptide-1 agonists, and novel combination drug products; Biovac-B, a recombinant hepatitis-B vaccine; Wepox, a recombinant human erythropoietin; Wosulin, a recombinant human insulin; and Glaritus, a recombinant insulin glargine. Further, the company offers delivery devices for insulin, including Dispopen disposable pen and Mypen reusable pen. Wockhardt Limited was founded in 1967 and is headquartered in Mumbai, India.
Prezzo delle azioni
$21.04
Ultima sincronizzazione: 2026-10-19
Capitalizzazione di mercato
$3.42B
Variazione (1 giorno)
-2.39%
Variazione (1 anno)
38.07%
Paese
IN
Scambia Wockhardt Limited (WOCKPHARMA)
Categoria
Healthcare
Rapporto P/S per Wockhardt Limited (WOCKPHARMA)
Rapporto P/S al October 2026 TTM: 8.92
Secondo gli ultimi rapporti finanziari e il prezzo delle azioni di Wockhardt Limited, il rapporto P/S attuale (TTM) è 8.92. Alla fine del 2024, era pari a 3.05.
Storico del rapporto P/S per Wockhardt Limited da 2004 a 2026
Rapporto P/S alla fine di ogni anno
| Anno | Rapporto P/S | Cambia |
|---|---|---|
| 2026 (TTM) | 8.92 | 20.16% |
| 2025 | 7.42 | 143.29% |
| 2024 | 3.05 | 264.90% |
| 2023 | 0.84 | -15.53% |
| 2022 | 0.99 | -46.30% |
| 2021 | 1.84 | 151.79% |
| 2020 | 0.73 | -44.52% |
| 2019 | 1.32 | -42.22% |
| 2018 | 2.28 | 6.29% |
| 2017 | 2.15 | -17.82% |
| 2016 | 2.62 | -47.40% |
| 2015 | 4.97 | 340.80% |
| 2014 | 1.13 | -73.70% |
| 2013 | 4.29 | 178.30% |
| 2012 | 1.54 | 50.46% |
| 2011 | 1.02 | 179.89% |
| 2010 | 0.37 | 1.87% |
| 2008 | 0.36 | -80.81% |
| 2007 | 1.87 | -22.86% |
| 2006 | 2.43 | -34.99% |
| 2005 | 3.73 | 10.06% |
| 2004 | 3.39 | 0.00% |
Rapporto P/S per aziende simili o concorrenti
| Azienda | Rapporto P/S | Differenza del rapporto P/S | Il paese |
|---|---|---|---|
| 10.31 | 15.65% |
US
|
|
| - | - |
SE
|
|
| - | - |
FR
|
|
| - | - |
IT
|
|
| 15.12 | 69.62% |
US
|
